Pictet & Cie (Europe) Sa Apellis Pharmaceuticals, Inc. Transaction History

Pictet & Cie (Europe) Sa

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$23.65 - $89.22 $2,223 - $8,386	-94 Reduced 1.36%	6,825 $259,000
Q2 2023 Aug 08, 2023	SELL	$76.68 - $93.31 $32,358 - $39,376	-422 Reduced 5.75%	6,919 $630,000
Q1 2023 May 01, 2023	BUY	$46.59 - $66.96 $3,680 - $5,289	79 Added 1.09%	7,341 $484,000
Q4 2022 Feb 08, 2023	SELL	$43.24 - $61.04 $1,513 - $2,136	-35 Reduced 0.48%	7,262 $0
Q2 2022 Aug 05, 2022	SELL	$35.07 - $59.21 $62,144 - $104,920	-1,772 Reduced 19.54%	7,297 $330,000
Q1 2022 May 04, 2022	BUY	$35.46 - $54.12 $96,947 - $147,964	2,734 Added 43.16%	9,069 $461,000
Q4 2021 Feb 02, 2022	BUY	$30.74 - $49.16 $194,737 - $311,428	6,335 New	6,335 $300,000
Q3 2021 Nov 10, 2021	SELL	$31.4 - $69.84 $283,887 - $631,423	-9,041 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$40.9 - $64.9 $47,444 - $75,284	1,160 Added 14.72%	9,041 $571,000
Q1 2021 May 10, 2021	BUY	$40.8 - $57.39 $321,544 - $452,290	7,881 New	7,881 $338,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.